[ad_1]
TipRanks
These 3 Penny Stocks Could Reach Over 100%, Says Roth Capital
Does high risk mean high reward? Not necessarily, say the pros on Wall Street. Citing specifically penny stocks, or stocks that trade below $ 5 per share, analysts advise caution as these names could still be at the start of the innings, or they could be facing an uphill battle that is just too steep. These stocks may face headwinds or have weak fundamentals, but analysts say there are start-ups that reflect promising opportunities, with low stock prices meaning you get a lot more for your money. Plus, even what appears to be a minor appreciation in stock prices can lead to massive percentage gains. All risks are not created equal. To this end, the pros recommend doing due diligence before making an investment decision. With that in mind, we turned to investment firm Roth Capital for inspiration. Company analysts have identified three compelling penny stocks, noting that each could climb more than 100% in the coming year. Using the TipRanks database, we found out what makes these three games so exciting, even with the risk involved. CohBar (CWBR) Focused on the development of mitochondria-based therapies (MBT), CohBar aims to find new treatments for diseases associated with aging and metabolic dysfunction. Based on the strength of its technology and its price of $ 0.96, Roth Capital believes now is the time to pull the trigger. Writing for the firm, analyst Elemer Piros points out that the CWBR has was able to transform 100 mitochondrial peptides into 1000 mitochondrials. based therapy (MBT). Scientists and company researchers around the world have found that mitochondrial peptides regulate several physiological systems, including risk factors that lead to cardiovascular and neurodegenerative diseases, obesity, diabetes, fatty liver disease, fibrous and inflammatory conditions and cancer. either continuously or intermittently to modulate biological functions, but it is difficult to administer them as therapies. Additionally, they also tend to have shorter half-lives. “CohBar has developed methods to modify peptides and plans to use modified analogs for clinical development,” commented Piros. The first for CWBR is CB4211, its optimized analogue of the mitochondrial derivative peptide MOTS-c. The company’s first clinical candidate completes a phase 1b trial in patients with fatty liver disease. According to management, 10 patients will be randomized to treatment with CB4211 and 10 to placebo, with results expected in the first quarter of 2021. Non-alcoholic fatty liver disease (NAFLD) is a condition defined by excessive accumulation of fat in the form of triglycerides (steatosis) in the liver in people who drink little or no alcohol. In addition, the company will also target non-alcoholic steatohepatitis (NASH), which is the most severe form of NAFLD. Piros acknowledges the competition in the field is fierce, but says “no winner can be identified, yet. ” Explaining this, the analyst said: “CB4211 offers a still unexplored, fundamental mechanism of action based on the natural control of homeostasis, which is lost due to environmental or genetic insults. The compound has been derived from natural mitochondrial peptides, with the aim of restoring, rebalancing homeostasis with the aim of reversing disease processes. Based on the above, Piros sees an attractive risk / reward in CWBR stocks. “[We] CohBar value based on a comparable universe of companies in the start-up or intermediate phase with platforms likely to generate several drug candidates. The average enterprise value of this group of companies is $ 268 million compared to CohBar at $ 38 million. We expect CohBar shares could trade in line with the average, ”the analyst concluded. To this end, Piros rates CWBR a buy with a price target of $ 8. If his thesis materializes, a potential gain of 741% over twelve months could be considered. (To see Piros’ history, click here) Overall, CWBR has a small, bullish but noisy analyst camp with positive expectations for its stock. Of the 2 analysts surveyed by TipRanks, both rate the stock as a buy. With a potential return of 557%, the consensus price target for the stock stands at $ 6.25. (See CWBR stock market analysis on TipRanks) Eyenovia (EYEN) Using its patented piezoelectric print delivery technology, Eyenovia is developing a pipeline of micro-dose therapeutics. With shares changing hands for $ 3.41 each, Roth Capital sees an attractive entry point for investors. In October, Eyenovia announced that a subsidiary of Bausch Health Companies had acquired an exclusive license in the United States and in Canada for the experimental microdose formulation of atropine ophthalmic solution (MicroPine), designed to reduce the progression of myopia in children aged 3 to 12 years. MicroPine, which is delivered through EYEN’s exclusive Optejet distributor, is progressing through Phase 3, with potential launch in 2025. Under the terms of the agreement, Bausch will assume oversight and expenses related to the ongoing trial. phase 3 CHAPERONE. In turn, Eyenovia will receive an upfront payment of $ 10 million and up to $ 35 million in approval and launch milestones, as well as royalties ranging in percentages ranging from mid-to-single-digit to mid-teens. gross margin on sales in the United States and Canada. Jonathan Aschoff of Capital tells clients that “the deal validates the technology and the market.” He adds that this agreement and the recent Asian MicroPine agreement with Arctic Vision, “combined with the savings of approximately $ 25 million in R&D for EYEN that these two agreements provide, should improve EYEN’s cash flow by approximately $ 100 million. dollars over the next few years. To that end, he argues that the company’s cash position should support its operations in the first half of 22nd. On top of that, assuming there are no COVID-related delays, Aschoff believes that EYEN is expected to be able to initiate the two Phase 3 VISION trials for MicroLine, its piezoelectric formulation of pilocarpine designed to replace reading glasses for three to four hours while addressing the instillation and tolerability issues associated with traditional eye drops, by YE20. That means trials can register in a few weeks, and results could be released in 2021.If that wasn’t enough, the company plans to file the MicroStat (its mydriasis candidate) NDA by YE20, along with the States. -United. Commercialization of MicroStat is expected to be made easier by the current pandemic, as physicians are more reluctant than ever to reuse the same pipette for multiple patients, and with reuse typically encompassing around 20 to 30 patients, the pipette has grown to approximately 20 to 30 patients. 30 times more expensive for the doctor, ”explained Aschoff. So it’s no surprise that Aschoff left a buy rating and a target price of $ 11 on the stock. Given this target, stocks could climb 223% next year. (To see Aschoff’s track record, click here) Looking at the Consensus Breakdown, 2 buys and no holds or sells have been issued in the past three months. Therefore, EYEN obtains a moderate purchase consensus rating. Based on the average price target of $ 8.50, stocks could gain 150% in the coming months. (See EYEN stock market analysis on TipRanks) Boqii Holding (BQ) Finally, we have Boqii Holding, which operates the largest online platform for pet products in China, with retail as its primary focus. online through third party Chinese online platforms and its own e-commerce site (Boqii Mall). Currently at $ 4.45 apiece, Roth Capital believes its stock price presents a chance to participate in the stock. Representing the company, analyst Darren Aftahi told his clients: “ BQ represents an early opportunity for investors to gain exposure to China’s premier pet-friendly ecosystem, which uniquely combines “community” and “commerce” in an omnichannel, verticalized online and offline platform. Part of what makes BQ so compelling is that while it operates primarily as an e-commerce business, it has an omnichannel and verticalized platform for pet products, according to Aftahi. Additionally, the company has integrated with offline channels such as pet stores and hospitals. The analyst argues that this not only expands consumer access points, but the online community also keeps users engaged with various forms of content and marketing, “enhancing the overall value of the platform for consumers. end customers ”. According to Frost & Sullivan, the growth of the pet population in China is predicted. to be among the fastest over the next few years, and is expected to match U.S. ownership (400 million pets) by 2024, up from around a third of that rate currently. “We believe BQ can see accelerated growth when we build on the continued adoption of e-commerce spending, with online pet retail spending expected to reach 52% of total retail. pets by 2024, “Aftahi commented. It should be noted that over 60% of sales come from BQ stores on third-party sites such as Tmall, JD.com and Pinduoduo, which Aftahi says “expands the reach of BQ’s brand.” Offering further explanation, the analyst said, “These sites are often the initial point of contact, and users can then be channeled into BQ’s online community for retargeting, giving BQ an advantage over the ownership of the sites. clients. In our view, BQ is poised to capture the growth of the e-commerce shift, which is diverse across access points, but under the BQ brand regardless. Everything BQ did prompted Aftahi to keep its purchase note as it was. Along with the call, he leaves the price target at $ 10, suggesting a potential upside of 123%. (To see Aftahi’s track record, click here) As for other analyst activities, it’s quiet. Because Aftahi is the only analyst to have published a review recently. (See BQ Stock Market Analysis on TipRanks) For great ideas for trading penny stocks at attractive valuations, visit Top Stocks to Buy from TipRanks, a newly launched tool that aggregates all information about stocks from TipRanks . only those of featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
[ad_2]
Source link